The platform
DeepC works the way your scientists do, designing formulations, clearing IP, qualifying safety, and producing the artifacts that go into the dossier. Every claim cited at the source.
What you do
The sixteen specialists organise around these. Two tiles preview the actual deliverable you would receive.
Job 01
From physicochemistry, IID precedent, and patent landscape to three to five candidate formulation cards with rationale and risk notes.
| Excipient | Function | % w/w |
|---|---|---|
| Active | API | 35 |
| HPMC K100M | Hydrophilic matrix former | 30 |
| Lactose monohydrate | Filler | 25 |
| Microcrystalline cellulose | Filler / binder | 8.5 |
| Magnesium stearate | Lubricant | 1 |
| Colloidal silicon dioxide | Glidant | 0.5 |
HPMC K100M selected as the primary release-control matrix at 30% w/w; concentration sits within IID precedent for oral MR products on Mirapex ER (NDA 022030). Lactose monohydrate and MCC chosen for direct-compression compatibility and to stabilise the API in a low-water-activity matrix.
Job 02
Anchor variants to a parent candidate. Target cost, dissolution, stability, or scale without losing what worked.
Job 03
FTO map with claim-by-claim blocking analysis, three non-infringing alternatives, then a USPTO-formatted draft for your counsel.
Job 04
High-concentration mAbs, bispecifics, ADCs, mRNA-LNPs, AAV gene therapy, cell therapy. Anchored to ICH Q5A-E, Q6B, Q13, Q14.
Job 05
ERA, extractables, leachables, nitrosamines, OEL, PDE. Klimisch-tiered evidence anchored to ICH M7(R2), Q3E, EMA HBEL, USP <1663>/<1664>, PQRI PODP.
Job 06
Stability trending, dissolution profiling, IVIVC, DoE, toxicology mining. Publication-ready figures with the methodology shown.
Proof
We benchmarked DeepC against our external toxicology consultancy on a substance-specific risk assessment. DeepC delivered a report our QP rated equal or stronger in around five minutes, versus the roughly one month our incumbent service took.
The roster
DeepC reads every question and routes it to the specialist whose deliverable answers it. Three suites for three modalities of work.
Research suite
07Formulation, optimization, FTO, patent drafting, VCM process design, analytics, research.
Biologics suite
03Biologics research, FTO, formulation and CMC. Antibodies, ADCs, bispecifics, mRNA-LNP, AAV, cell therapy.
Safety suite
06ERA, extractables, leachables, nitrosamines, OEL, PDE. Dossier-ready regulatory output.
Grounded and verified
Physics checked. Anchored to ICH, EMA, USP, PQRI, addressable to the clause. Cited to the primary record.
Reality Anchor
Anchored frameworks
Reasoning surface
The platform underneath
When enabled for an organization, DeepC traverses a connected representation of substances, formulations, adverse events, trials, conditions, reactions, patents, and regulatory statuses. Multi-hop questions become tractable.
Drag, drop, paste, or attach PDFs, DOC/DOCX, spreadsheets, JSON, XML, HTML, plain text, and images. PDFs are parsed asynchronously for full-text extraction so the agents can cite from them.
Four kinds of notes survive across conversations: user, feedback, project, reference. Settings, Memory shows everything stored; you can inspect, edit, or remove individual entries, or turn the feature off.
Conversations and uploads group into projects with role-based access. Owner, Editor, and Viewer roles. Comments anchor to specific findings, formulations, claims, or thresholds.
Every factual claim renders an inline superscript that anchors to a Sources dropdown. Cited and Consulted entries are split. Multi-source claims stack so each underlying source is traceable independently.
Tell us what you are working on (molecule, indication, stage, open question).
A formulation lead will be in touch within a business day.